---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-000630"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:05:21.458700+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q1 net loss narrows to $14.1M; cash runway extends into 2028

## Summary
- Net loss $14.1M ($0.52/diluted share) vs $26.8M ($1.00) a year ago; revenue $29.4M down 23% YoY.
- Cash, equivalents and restricted cash $273.8M at March 31, 2025; runway extended into 2028 via resource re-allocation.
- Received initial EU approval milestone payment from CSL Seqirus for KOSTAIVE COVID-19 vaccine.
- ARCT-032 (CF) Phase 2 interim data from first two cohorts expected mid-2025; enrollment to complete by year-end.
- ARCT-810 (OTC) Phase 2 interim data expected Q2 2025; FDA Fast Track granted for H5N1 vaccine ARCT-2304.

## SEC filing metadata
- accession: 0001193805-25-000630
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380525000630/0001193805-25-000630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380525000630/e664482_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-000630
- JSON: https://secwatch.observer/filing/0001193805-25-000630.json
- Plain text: https://secwatch.observer/filing/0001193805-25-000630.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.